Vaccinex's CEO, Chairman To Inject $4M To Fund The Lead Program

Vaccinex Inc VCNX has announced a private placement of approximately 5.9 million at $1.11 per share for about $6.6 million gross proceeds

  • The private placement is expected to close on January 31.
  • Participants in the private placement include entities controlled by Maurice Zauderer, President & CEO of Vaccinex, and Albert Friedberg, Vaccinex's Chairman.
  • Each of them has purchased $2 million worth of shares.
  • Other investors include an entity controlled by Jacob Frieberg, another board member of Vaccinex, and additional new & existing shareholders, who purchased the remaining $2.6 million worth of shares.
  • Vaccinex will use the funds to develop its lead drug candidate, pepinemab, in cancer & neurodegenerative disease and for working capital & general corporate purposes. 
  • Related: Vaccinex Posts Two Complete Responses In Pepinemab Combo Trial In Head & Neck Cancer.
  • Vaccinex also announced that during the month of January, before entering into the stock purchase agreement, Vaccinex sold approximately $3.5 million of shares in January 2022 for an average sales price of $1.16/share under its existing open market sales agreement with Jefferies LLC
  • This brings the total of new equity financing to date in 2022 to $10.1 million.
  • Price Action: VCNX shares are up 7.11% at $0.98 during the premarket session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!